-$0.15 Earnings Per Share Expected for CEL-SCI Co. (NYSE:CVM) This Quarter

Brokerages predict that CEL-SCI Co. (NYSE:CVMGet Rating) will post ($0.15) earnings per share (EPS) for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for CEL-SCI’s earnings. CEL-SCI posted earnings of ($0.25) per share during the same quarter last year, which indicates a positive year-over-year growth rate of 40%. The company is scheduled to issue its next quarterly earnings report on Monday, January 1st.

According to Zacks, analysts expect that CEL-SCI will report full-year earnings of ($0.49) per share for the current fiscal year. For the next fiscal year, analysts forecast that the company will post earnings of $0.91 per share. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that follow CEL-SCI.

CEL-SCI (NYSE:CVMGet Rating) last announced its quarterly earnings data on Monday, February 14th. The company reported ($0.20) earnings per share (EPS) for the quarter.

Separately, StockNews.com began coverage on CEL-SCI in a research note on Thursday, March 31st. They issued a “sell” rating on the stock.

Shares of NYSE CVM traded up $0.35 during mid-day trading on Tuesday, hitting $3.27. The company had a trading volume of 862,945 shares, compared to its average volume of 1,443,734. CEL-SCI has a 1-year low of $2.49 and a 1-year high of $27.28. The company has a quick ratio of 11.94, a current ratio of 12.56 and a debt-to-equity ratio of 0.25. The stock has a market cap of $141.51 million, a P/E ratio of -3.55 and a beta of 2.17. The business’s 50-day moving average price is $3.59.

CEL-SCI Company Profile (Get Rating)

CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of head and neck cancer. Its Ligand Epitope Antigen Presentation System (LEAPS), a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer.

Read More

Get a free copy of the Zacks research report on CEL-SCI (CVM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for CEL-SCI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CEL-SCI and related companies with MarketBeat.com's FREE daily email newsletter.